Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech

The extent of rare side effects of mRNA vaccines for coronavirus disease 2019 (COVID-19) remains unclear. Several cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following COVID-19 vaccination have been reported. We herein report a 72-year-old man who presented with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Minami, Sekiguchi, Yuta, Sasaki, Masato, Inaba, Shunsuke, Oyama, Sakino, Inoue, Yuichi, Warabi, Masahiro, Ohashi, Kenichi, Inoshita, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593166/
https://www.ncbi.nlm.nih.gov/pubmed/36184535
http://dx.doi.org/10.2169/internalmedicine.9807-22
_version_ 1784815099277475840
author Suzuki, Minami
Sekiguchi, Yuta
Sasaki, Masato
Inaba, Shunsuke
Oyama, Sakino
Inoue, Yuichi
Warabi, Masahiro
Ohashi, Kenichi
Inoshita, Seiji
author_facet Suzuki, Minami
Sekiguchi, Yuta
Sasaki, Masato
Inaba, Shunsuke
Oyama, Sakino
Inoue, Yuichi
Warabi, Masahiro
Ohashi, Kenichi
Inoshita, Seiji
author_sort Suzuki, Minami
collection PubMed
description The extent of rare side effects of mRNA vaccines for coronavirus disease 2019 (COVID-19) remains unclear. Several cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following COVID-19 vaccination have been reported. We herein report a 72-year-old man who presented with a fever after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine. He was diagnosed with acute kidney injury due to myeloperoxidase-ANCA-associated vasculitis and was treated with intermittent hemodialysis, high-dose prednisolone, and intravenous rituximab. His general symptoms and renal impairment subsequently improved. When systemic symptoms are prolonged or renal abnormalities appear after COVID-19 vaccination, the possibility of AAV should be considered.
format Online
Article
Text
id pubmed-9593166
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-95931662022-11-07 Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech Suzuki, Minami Sekiguchi, Yuta Sasaki, Masato Inaba, Shunsuke Oyama, Sakino Inoue, Yuichi Warabi, Masahiro Ohashi, Kenichi Inoshita, Seiji Intern Med Case Report The extent of rare side effects of mRNA vaccines for coronavirus disease 2019 (COVID-19) remains unclear. Several cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following COVID-19 vaccination have been reported. We herein report a 72-year-old man who presented with a fever after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine. He was diagnosed with acute kidney injury due to myeloperoxidase-ANCA-associated vasculitis and was treated with intermittent hemodialysis, high-dose prednisolone, and intravenous rituximab. His general symptoms and renal impairment subsequently improved. When systemic symptoms are prolonged or renal abnormalities appear after COVID-19 vaccination, the possibility of AAV should be considered. The Japanese Society of Internal Medicine 2022-10-01 2022-10-01 /pmc/articles/PMC9593166/ /pubmed/36184535 http://dx.doi.org/10.2169/internalmedicine.9807-22 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Suzuki, Minami
Sekiguchi, Yuta
Sasaki, Masato
Inaba, Shunsuke
Oyama, Sakino
Inoue, Yuichi
Warabi, Masahiro
Ohashi, Kenichi
Inoshita, Seiji
Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
title Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
title_full Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
title_fullStr Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
title_full_unstemmed Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
title_short Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech
title_sort antineutrophil cytoplasmic antibody-associated vasculitis after covid-19 vaccination with pfizer-biontech
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593166/
https://www.ncbi.nlm.nih.gov/pubmed/36184535
http://dx.doi.org/10.2169/internalmedicine.9807-22
work_keys_str_mv AT suzukiminami antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT sekiguchiyuta antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT sasakimasato antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT inabashunsuke antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT oyamasakino antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT inoueyuichi antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT warabimasahiro antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT ohashikenichi antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech
AT inoshitaseiji antineutrophilcytoplasmicantibodyassociatedvasculitisaftercovid19vaccinationwithpfizerbiontech

Ejemplares similares